GlassScriptPhysician profile
Angela Love
NPI 1255697140
$589.39
in general payments reported to CMS, 2019-2025
15 companies · $51.66 in 2025
The $51.66 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $75.59 · 2022: $26.50 · 2023: $183 · 2024: $252 · 2025: $51.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $471 · Education: $16.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $471.06 |
| Education | $16.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $146.91 | 2021-2025 | Nucala |
| Astrazeneca Pharmaceuticals LP | $80.70 | 2021-2024 | Fasenra, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.93 | 2022-2023 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Amgen INC. | $65.57 | 2024 | Tezspire |
| Abiomed | $41.20 | 2024 | Impella |
| Axsome Therapeutics, INC. | $23.89 | 2024 | Sunosi |
| Grifols USA, LLC | $22.73 | 2021 | |
| Inogen, INC. | $20.33 | 2024 | |
| Baxter Healthcare | $19.35 | 2023 | Hillrom - Life 2000 Ventilation System |
| Abbvie INC. | $19.27 | 2024 | |
| Merck Sharp & Dohme LLC | $18.66 | 2023 | Verquvo |
| Genzyme Corporation | $17.60 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $16.44 | 2024 | Dupixent |
| Insmed, INC. | $16.24 | 2024 | Arikayce |
| Mylan Specialty L.P. | $14.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Love listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.